The latest announcement is out from Outlook Therapeutics ( (OTLK) ).
On March 13, 2025, Outlook Therapeutics, Inc. completed the issuance of an unsecured convertible promissory note worth $33.1 million to Avondale Capital, LLC, using the proceeds to fully repay its existing obligations with Streeterville Capital, LLC. At the 2025 Annual Meeting held on March 11, stockholders approved several proposals, including increasing the authorized shares of common stock from 60 million to 260 million, electing Class III directors, and ratifying KPMG LLP as the independent auditor, reflecting strategic moves to strengthen the company’s financial and operational framework.
More about Outlook Therapeutics
Outlook Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for ophthalmic diseases. The company is primarily engaged in creating innovative treatments for vision-related conditions, aiming to address unmet medical needs in the eye care market.
YTD Price Performance: -28.16%
Average Trading Volume: 817,788
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $49.31M
Learn more about OTLK stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com